This summer RCSI welcomed our very first cohort of ten international students as part of our Inaugural RCSI StAR International Summer Internship Programme. Students came from Washington University, Cornell University, University of California, Berkeley, University of Oregon, Queen’s University Belfast, University of Liverpool and TCD to spend two months in laboratories around RCSI. To mark the end of the programme we held a research symposium where students show-cased their research and experience. It was a huge success, with Kieran White, University of Liverpool winning the overall prize for the best presentation on ‘Nanotherapeutics for Glioblastoma’ (supervisor Professor Annett Byrne). Kieran has already accepted a PhD position with Prof Byrne on her GlioTrain programme. Thanks to Prof Darran O’Connor and Prof Tracy Robson (MCT) for leading this initiative.
We will also be running the StAR summer internship next year – stay tuned. Here is the link to last year’s programme which will be updated within the next month: http://www.rcsi.ie/starugprogramme
A fantastic few weeks of research is now completed, culminating in the Wrap Up Symposium on Friday, July 27th, 2018. This year not only had we our own students from RCSI but we also welcomed undergraduate students from Hoshi University, Tokyo, Japan; Soochow University, Suzhou, China; the RCSI StAR Summer Internship Programme; FutureNeuro and the Faculty of Dentistry. There was great stuff being done on a number of fronts, not only in the labs but also out on our clinical sites as well as an increase in the number of students involved in some fab systematic reviews. It was incredible to see the breadth of research done by our undergraduate students in such a short period of time. It is a credit to them, their research supervisors and teams. We eagerly look forward to next year’s programme.
Some insights from student’s perspective:
“It was educational in a different way; I expected to learn more about the disease I am working with get an outcome but instead, I feel like I am better equipped to analyse papers and data and methods that are very useful in the future as a clinician.”
“Amazing! Big thanks to Gill and Sarah O’Neill”
“It was a knowledgeable and valuable learning experience that was never dull in any way.”
The way we act very much depends on our surroundings; not the least on the weather conditions. In a similar way, cells in our body very much depend on what is going on around them. It has been known for a long time that the specific niches in which cells reside impact on the cellular phenotype. While most researchers have looked at chemical signals – either released into the environment or reflecting the composition of the extracellular matrix – it is becoming increasingly clear that also physical properties, such as stiffness and topography, are sensed by a wide variety of cells and influences their decisions.
It is our pleasure to welcome Prof Viola Vogel this Monday at RCSI for the MCT research seminar.
July 16th, 4.00 pm, Albert Lecture Theatre “How does the mechanobiology of extracellular matrix steer cancer progression?”
Prof Vogel and her laboratory at ETH Zurich have pioneered the field of mechanobiology. Her earlier work focused on how proteins act as mechanochemical switches to transduce mechanical signals from the ECM into the cell. More recent work addresses the importance of tissue strain in the development of tumours. Prof Vogel will also share her latest results on how physical constraints affect decision making of macrophages.
Anyone who is interested in getting a different viewing angle on cancer and immunity is heartily invited! To steer your personal decision making towards attending the talk, refreshments will be served from 3.30 pm on in the Atrium.
Global collaborations can help answer fundamental questions that are resistant even to national endeavours. Drs Mark McCormack and Christopher Whelan (MCT) and Professors Kieran Murphy (Psychiatry) and John Waddington (Emeritus, MCT) have participated in an important international study, the results of which have just been published in Science [2018 Jun 22;360(6395)] under the auspices of the Brainstorm Consortium. This landmark study, ‘Analysis of shared heritability in common disorders of the brain‘, analyses genetic data assembled globally from 265,218 patients having one of 25 neuropsychiatric disorders and 784,643 control participants, together with 1,191,588 individuals having 17 other, potentially relevant characteristics. Psychiatric disorders share an unexpected degree of common genetic risk: for example, genes associated with risk for schizophrenia are also associated, to varying extents, with significant risk for bipolar disorder, major depressive disorder, autism spectrum disorder, attention deficit/hyperactivity disorder, obsessive-compulsive disorder and anorexia nervosa; in contrast, neurological disorders such as epilepsy, stroke, Parkinson’s disease, migraine and multiple sclerosis appear more genetically distinct from one another. This highlights the importance of common genetic variation as a risk factor across psychiatric disorders.
The Curtis Clock laboratory has a real interest in metabolism, which is a really broad term and means different things to different people. We are interested in how different fuels (sugars , fats, proteins) are metabolised (broken down) within immune cells, and if this has an impact on how that immune cell functions. The key metabolic organelle within a cell is the mitochondria, that is where the breakdown parts of these fuels end up and are converted to energy (ATP). We are a Clock lab, so our raison d’etre (so to speak) is to unravel how different fuels are metabolised within immune cells at different times of day and how the mitochondria work at different times of day, and how that impacts the response of the immune cell at that time of day. This is what we now term “Circadian Immunometabolism”. This leads me on nicely to our title, before the age of electricity, our forefathers never ate in the middle of the night, we believe that our immune system becomes dysfunctional when it has to deal with food during a time when we now believe our immune system is undergoing repair and restoration. So to begin to get at these big questions, Mariana and George have two exciting projects ongoing. Mariana, who is a postdoc in the laboratory, will show how our mitochondria are changing over the course of the day in dendritic cells (these are cells of the innate immune system and are the ones that feed information to our adaptive immune system) (see Fig. 1). The title of her talk is
“Those mitochondria have got rhythms! Mitochondrial activity and antigen processing in dendritic cells is dependent on the molecular clock protein BMAL1”.
George, a PhD student in the lab, is dissecting down into the cells to figure out how the electron transport chain (the side of action for ATP synthesis) is controlled by the clock. The title of his talk is
“Metabolic pathways in a macrophage lacking a molecular clock”
More details of what we do can be found here: www.Curtisclocklab.com
We are delighted to have raised €309 for the MS fundraiser on Wednesday 30th May!! Thanks to all who baked and donated cakes for the event. A massive thank you to Bretzel Bakery for all the delicious pastries and sourdough breads and a raffle ticket for Bloom.
Pathological blood vessel formation (angiogenesis), or the inability of endothelial cells to perform their physiological function (endothelial dysfunction), are defining features of disease. The endothelium actively controls vessel integrity, vascular growth and remodelling, tissue growth and metabolism, immune responses, cell adhesion, angiogenesis, haemostasis and vascular permeability. It is, therefore, a vital and largely unexploited target for novel therapies.
Prof Tracy Robson’s team have identified and characterised a novel anti-angiogenic protein, FK506 binding protein like – FKBPL, significantly advancing our understanding of the anti-angiogenic process, in particular, how tumours recruit blood vessels to support their growth. This led to a collaborative study with Almac Discovery to develop therapeutic peptides based on FKBPL’s active domain to explore their potential in cancer by targeting the ability of tumours to recruit blood vessels to grow, invade and metastasise beyond the site of the primary tumour. The team are also testing the ability of these peptides to sensitise tumours to current therapies and to target cancer stem cells that lead to the onset of resistance and/or recurrent disease. Importantly, these studies led to a ‘first in man’ phase I clinical in cancer patients where the clinical candidate drug, ALM201, was very well tolerated over a wide range of doses. Prof Robson’s team (Dr Stephanie Annett and Dr Gillian Moore) will discuss this data together with new data suggesting a strong role for FKBPL in vascular endothelial dysfunction and possible implications therefore in other diseases associated with vascular disease.
In honour of World MS Day on the 30 May 2018; the Molecular and Cellular Department in the Royal College of Surgeons Ireland along with Trinity College Dublin, MS Society Ireland and Novartis have joined together to create an MS Research Network event.
The event will comprise of three parts; the first is a World MS Day Fundraiser located in the main foyer of RCSI between 8.30 – 10 am, please come and support the #bringinguscloser campaign. The second is a Researcher Forum for scientists working on MS in Ireland, with the aim to establish an official researcher network to enhance collaboration, visibility, and congeniality. The third is a Public Event to launch the most recent MS Society report and inform the public of the importance and relevance of MS research that is conducted in Ireland.
All are welcome to these events (see below details). To register for the day event, email Harriet Doig at email@example.com, to register for the evening event, email Emma Kinnane at firstname.lastname@example.org.
Written and organised by Claire McCoy
World MS Day Fundraiser – Royal College of Surgeons, Main Foyer. 8.30 – 10am
Researcher Forum – Royal College of Surgeons in Ireland, Tutorial Room 2/3
12.00 Meet and Greet (lunch is provided)
12.30 Harriet Doig (MS Society Ireland). ‘The value of a research network in Ireland’
12.40 Claire McCoy (RCSI). ‘The importance of microRNA-155 in Multiple Sclerosis and my contribution to an MS research network’
13.10 Eric Downer (Trinity College Dublin). ‘Exploring Exercise & Cannabinoids as Therapeutic Targets in MS’
13.40 Una Fitzgerald (NUIG). ‘My research and how I can contribute to an MS research network’
14.15 Tea Break
14.45 Jill Moffat (Queen’s University Belfast). ‘The Northern Ireland MS network – challenges and opportunities’
15.00 Denise Fitzgerald (Queen’s University Belfast) ‘My Research and how the Northern Ireland MS network benefits it’
15.30 Mary Fitzsimons (Beaumont Hospital). ‘How to build an MS electronic patient record, lessons from the epilepsy lighthouse project’
15.45 Alexis Donnelly (Patient advocate). ‘How patients can help build MS research’
Public Event – Trinity Biomedical Sciences Institute, Trinity College Dublin
18.00 MS Society Report Launch
18.20 Clinician – Orla Hardiman (Beaumont Hospital and Trinity College Dublin)
18.40 Researcher – Claire McCoy (RCSI)
19.00 Patient Advocate – Joan Jordan (Patient Advocate)
Sepsis is a major challenge in the intensive care unit, where it is one of the leading causes of death. It arises unpredictability and can progress rapidly. Globally there are an estimated 30 million cases of sepsis each year which results in more than 8 million deaths in adults and 5 million deaths in children. Of those who do survive a further one third will die in the following 12 months, those who survive often face life-long consequences, such as new physical, mental and cognitive problems. Although this number is gathered from several sources, all content to the fact that it is likely an underestimate and therefore may very well be the leading cause of mortality worldwide. Currently, there are no approved drugs on the market to control the underlying pathophysiology that triggers the dysregulated host response to sepsis and therefore the management plan focuses on reducing the infection through the use of aggressive intravenous antibiotic therapy and source control. Therefore the cardiovascular infection research group is investigating a therapeutic option that acts early to prevent bacteria binding to the host vascular endothelial cell in the first place would be commercially advantageous as it will prevent the infection from progressing to septic shock and a life-threatening situation as a result of multi-organ failure.
Funded by: Science Foundation Ireland, Enterprise Ireland, Irish Research Council, British Heart Foundation, Health Research Board, Wellcome Trust
Did you ever wonder what was the significance of the white coat ceremony and what impact it can have on students and faculty who attend?
Dr. Orna Tighe, Dr. Judith Strawbridge, Dr. Alice McGarvey and Prof Hannah McGee explain the evolution of this ceremony at RCSI on the blog of Journal of Interprofessional Care. They touch on the history of the white coat ceremony, it’s associated symbolism, how this ceremony became a tradition in RCSI and has now developed into a unique interprofessional White Coat ceremony, offering an opportunity for multidisciplinary healthcare professionals to develop interprofessional socialization at an early point in their education. The philosophy and the value of this ceremony in RCSI are discussed.
Have a look at some messages from the story and read the original here.
“We recognized that the ceremony needed to be more than just bringing students together and consequently it was developed to ensure that student voice was central, while emphasizing institutional support for interprofessional collaboration”…
“In summary, our experience suggests that the initial power of the white coat metaphor has evolved within RCSI to deliver what is a novel inspirational Interprofessional Ceremony in the very first week of the students’ programs”